Recursion Pharmaceuticals Stock Surges 10% As Nvidia-Powered Supercomputer Completion Sparks Investor Optimism
Recursion Pharmaceuticals Stock Surges 10% As Nvidia-Powered Supercomputer Completion Sparks Investor Optimism
Related Link: HSBC Analyst Sees Nvidia Stock Climbing Another 50% On Strong Pricing Power, AI RoadmapRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) made waves Monday with the announcement of the completion of its groundbreaking BioHive-2 supercomputer, as well as the notable surge in its stock that followed.
Recursion Pharmicals, Inc.（纳斯达克股票代码：RXRX）周一宣布其开创性的BioHive-2超级计算机竣工，随后其股票大幅上涨，引起了轰动。
RXRX Price Action: Recursion Pharmaceutical shares closed at $9.48 on Monday, reflecting an impressive gain of 10.2% compared to the previous day's close, according to Benzinga Pro.
RXRX价格走势：根据Benzinga Pro的数据，Recursion Pharmaceutical股价周一收于9.48美元，与前一天的收盘价相比上涨了10.2％。
What Happened: Recursion's stock surge came after the company announced the completion of its new Nvidia Corp (NASDAQ:NVDA)-powered AI supercomputer. The computer, called BioHive-2, is powered by 63 Nvidia H100 systems with a total of 504 Nvidia H100 Tensor Core GPUs, interconnected by Nvidia Quantum-2 InfiniBand networking.
发生了什么：Recursion的股票飙升是在该公司宣布完成其基于Nvidia Corp（纳斯达克股票代码：NVDA）的新型人工智能超级计算机之后发生的。这台名为 BioHive-2 的计算机由 63 个 Nvidia H100 系统提供动力，共有 504 个 Nvidia H100 Tensor Core GPU，由 Nvidia Quantum-2 InfiniBand 网络互连。
Related Link: HSBC Analyst Sees Nvidia Stock Climbing Another 50% On Strong Pricing Power, AI Roadmap
相关链接：汇丰银行分析师认为，由于强劲的定价能力和人工智能路线图，英伟达股价将再上涨50％
The completion of the supercomputer signifies a significant milestone for Recursion in its quest to revolutionize drug discovery through advanced computational methods. The company's innovative approach, coupled with the unveiling of this state-of-the-art supercomputer, has evidently resonated positively with investors, driving up demand for Recursion's shares.
超级计算机的建成标志着Recursion寻求通过先进的计算方法彻底改变药物发现的过程中的一个重要里程碑。该公司的创新方法，加上这款最先进的超级计算机的问世，显然引起了投资者的积极共鸣，推动了对Recursion股票的需求。
"With BioHive-2 now online, we have significantly more computational horsepower to accelerate our use of our ever-growing dataset, extending our ability to train larger and more generalizable foundation models and AI agents to industrialize our drug discovery efforts," said Ben Mabey, chief technology officer at Recursion.
Recursion首席技术官本·马比表示：“随着BioHive-2现已上线，我们的计算能力要大大提高，可以加速我们对不断增长的数据集的使用，从而扩展我们训练更大、更具通用性的基础模型和人工智能代理的能力，从而将我们的药物发现工作工业化。”
Monday's trading activity saw Recursion's stock trade as high as $10.40, showcasing the heightened investor interest. With a market capitalization of $2.248 billion, Recursion Pharmaceuticals continues to capture attention within the pharmaceutical and technology sectors, fueled by its ambitious goals and pioneering advancements in AI-driven drug discovery.
在周一的交易活动中，Recursion的股票交易价格高达10.40美元，这表明投资者的兴趣有所增加。Recursion Pharmicals的市值为22.48亿美元，在其雄心勃勃的目标和人工智能驱动的药物发现方面的开创性进步的推动下，继续引起制药和技术领域的关注。
"Accelerated computing, combined with the power of generative AI, is propelling the pharmaceutical industry into a new, advanced era of drug discovery," said Rory Kelleher, global head of business development for life sciences at Nvidia.
英伟达生命科学业务发展全球主管罗里·凯勒赫表示：“加速计算加上生成式人工智能的力量，正在推动制药行业进入一个新的先进药物发现时代。”
"BioHive-2, powered by NVIDIA DGX AI supercomputing, is poised to accelerate the development of additional industry-leading foundation models across biology, chemistry, and healthcare."
“由NVIDIA DGX AI超级计算提供支持的BioHive-2有望加快生物学、化学和医疗保健领域其他行业领先基础模型的开发。”
Image: courtesy of Recursion Pharmaceuticals.
图片：由 Recursion Pharmicals 提供。
